Doctor with patient. Image credit: Canva
A clinical trial led by Hoyoung M. Maeng, M.D., Associate Research Physician in the Center for Immuno-Oncology, is researching the safety and tolerability of intratumoral (IT) injection of tolododekin alfa (ANK-101) for adults with advanced solid tumors.
The study will be conducted in three parts. In Part 1, participants with superficial lesions will receive ANK-101 as a single agent; in Part 2, participants with visceral lesions will receive ANK-101 as a single agent; in Part 3, participants with cutaneous squamous cell carcinoma will receive ANK-101 in combination with cemiplimab.
The trial will take place at the NIH Clinical Center in Bethesda, Maryland, and there is no cost for medical care received at the Clinical Center.
For more information, please contact the NCI Cancer Information Service at 1-888-624-1937 or nciinfo@mail.nih.gov
Clinicaltrials.gov identifier: NCT06171750
NCI Protocol ID: IRB001924
Official Title: A Phase I Open-Label, Dose Escalation Study of the Safety and Tolerability of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
The Center for Cancer Research is NCI’s internal cancer center, a publicly funded organization working to improve the lives of cancer patients by solving important, challenging and neglected problems in cancer research and patient care. Highly trained physician-scientists develop and carry out clinical trials to create the medicines of tomorrow treating patients at the world’s largest dedicated research hospital on the campus of the National Institutes of Health in Bethesda, Maryland.
For more information on CCR clinical trials click here, and subscribe to have the latest CCR clinical trials sent directly to your inbox.
